{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:07:13Z","timestamp":1761894433727},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) differs in histological and clinical presentation from classical Hodgkin lymphoma (cHL). The typical morphologic signs of NLPHL are atypical \u201clymphocytic and histiocytic\u201d (L&amp;H) cells, which are surrounded by a non-neoplastic nodular background of small lymphocytes of B-cell origin. The NLPHL cells are positive for CD45, CD19, CD20, CD22 and CD79a, but lack expression of CD15 and CD30, the typical markers for cHL. NLPHL patients are predominantly of male gender with a median age of 37 years. Patients often present in early stages (63%) and rarely have B-symptoms (9%). Treatment of NLPHL patients using standard Hodgkin lymphoma (HL) protocols leads to complete remission (CR) in more than 95% of patients. Survival and freedom from treatment failure (FFTF) are worse in advanced-stage patients than in early-stage patients. Thus, patients in advanced and in early stages with unfavorable risk factors are treated similarly to cHL patients. In contrast, patients with early-stage NLPHL without risk factors can be sufficiently treated with reduced intensity programs having less severe adverse effects. As a result, treatment of early NLPHL is less clearly defined, including radiotherapy in extended field (EF) or involved field (IF) technique, combined modality treatment, and, more recently, monoclonal antibody rituximab. Watch and wait strategy plays an important role in pediatric oncology to avoid adverse effects associated with therapy.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.266","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"266-272","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma"],"prefix":"10.1182","volume":"2006","author":[{"given":"Lucia","family":"Nogova\u0301","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rudiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702054880600_R1","doi-asserted-by":"crossref","unstructured":"Jost LM, Stahel RA. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin\u2019s disease. Ann Oncol. 2005;16 Suppl 1:i54\u201355.","DOI":"10.1093\/annonc\/mdi814"},{"key":"2019111702054880600_R2","unstructured":"Connors JM. Lymphocyte-predominant Hodgki\u2019s Lymphoma. American Society of Hematology Education Program Book. 2001:187\u2013190."},{"key":"2019111702054880600_R3","doi-asserted-by":"crossref","unstructured":"Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease. J Clin Oncol. 1999;17:776\u2013783.","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"2019111702054880600_R4","doi-asserted-by":"crossref","unstructured":"Burns BF, Colby TV, Dorfman RF. Differential diagnostic features of nodular L & H Hodgkin\u2019s disease, including progressive transformation of germinal centers. Am J Surg Pathol. 1984;8:253\u2013261.","DOI":"10.1097\/00000478-198404000-00002"},{"key":"2019111702054880600_R5","unstructured":"Jaffe E, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon, France: 2001;240\u2013243."},{"key":"2019111702054880600_R6","doi-asserted-by":"crossref","unstructured":"Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753\u20133758.","DOI":"10.1182\/blood-2003-02-0626"},{"key":"2019111702054880600_R7","doi-asserted-by":"crossref","unstructured":"Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin\u2019s lymphoma\u2014molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11\u201318.","DOI":"10.1016\/S1470-2045(03)01319-6"},{"key":"2019111702054880600_R8","doi-asserted-by":"crossref","unstructured":"Braeuninger S, Kueppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominance Hodgkin disease represent clonal populations of germinal center-derived tumor cells. Proc Natl Acad Sci U S A. 1997:9337\u20139342.","DOI":"10.1073\/pnas.94.17.9337"},{"key":"2019111702054880600_R9","doi-asserted-by":"crossref","unstructured":"Marafioti T, Pozzobon M, Hansmann ML, Delsol G, Pileri SA, Mason DY. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 2004;103:188\u2013193.","DOI":"10.1182\/blood-2003-05-1487"},{"key":"2019111702054880600_R10","unstructured":"Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889\u20131899."},{"key":"2019111702054880600_R11","doi-asserted-by":"crossref","unstructured":"Stein H, Hansmann ML, Lennert K, Brandtzaeg P, Gatter KC, Mason DY. Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin\u2019s disease of nodular subtype contain J chain. Am J Clin Pathol. 1986;86:292\u2013297.","DOI":"10.1093\/ajcp\/86.3.292"},{"key":"2019111702054880600_R12","doi-asserted-by":"crossref","unstructured":"Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin\u2019s disease cell lines. Blood. 1995;85:780\u2013789","DOI":"10.1182\/blood.V85.3.780.bloodjournal853780"},{"key":"2019111702054880600_R13","unstructured":"Timens W, Visser L, Poppema S. Nodular lymphocyte predominance type of Hodgkin\u2019s disease is a germinal center lymphoma. Lab Invest. 1986;54:457\u2013461."},{"key":"2019111702054880600_R14","unstructured":"Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin\u2019s disease. Am J Pathol. 1989;135:351\u2013357."},{"key":"2019111702054880600_R15","unstructured":"Kamel OW, Gelb AB, Shibuya RB, Warnke RA. Leu 7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin\u2019s disease from nodular sclerosing Hodgkin\u2019s disease, T-cell-rich B-cell lymphoma and follicular lymphoma. Am J Pathol. 1993;142:541\u2013546."},{"key":"2019111702054880600_R16","doi-asserted-by":"crossref","unstructured":"Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin\u2019s lymphoma arising in patients treated for Hodgkin\u2019s disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol. 1991;2 Suppl 2:83\u201392.","DOI":"10.1093\/annonc\/2.suppl_2.83"},{"key":"2019111702054880600_R17","doi-asserted-by":"crossref","unstructured":"Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin\u2019s disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997;26:359\u2013368.","DOI":"10.3109\/10428199709051786"},{"key":"2019111702054880600_R18","doi-asserted-by":"crossref","unstructured":"Hansmann ML, Wacker HH, Radzun HJ. Paragranuloma is a variant of Hodgkin\u2019s disease with predominance of B-cells. Virchows Arch A Pathol Anat Histopathol. 1986;409:171\u2013181.","DOI":"10.1007\/BF00708326"},{"key":"2019111702054880600_R19","doi-asserted-by":"crossref","unstructured":"Wickert RS, Weisenburger DD, Tierens A, Greiner TC, Chan WC. Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood. 1995;86:2312\u20132320.","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312"},{"key":"2019111702054880600_R20","unstructured":"Alkan S, Ross CW, Hanson CA, Schnitzer B. Epstein-Barr virus and bcl-2 protein overexpression are not detected in the neoplastic cells of nodular lymphocyte predominance Hodgkin\u2019s disease. Mod Pathol. 1995;8:544\u2013547."},{"key":"2019111702054880600_R21","doi-asserted-by":"crossref","unstructured":"Wang T, Lasota J, Hanau CA, Miettinen M. Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value. Apmis. 1995;103:655\u2013662.","DOI":"10.1111\/j.1699-0463.1995.tb01419.x"},{"key":"2019111702054880600_R22","doi-asserted-by":"crossref","unstructured":"Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin\u2019s disease. Am J Pathol. 2001;159:1807\u20131814.","DOI":"10.1016\/S0002-9440(10)63027-1"},{"key":"2019111702054880600_R23","doi-asserted-by":"crossref","unstructured":"Pettersson M, Sundstrom C, Nilsson K, Larsson LG. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood. 1995;86:2747\u20132753.","DOI":"10.1182\/blood.V86.7.2747.2747"},{"key":"2019111702054880600_R24","doi-asserted-by":"crossref","unstructured":"Ru\u0308diger TO, Ott MM, Mu\u0308ller-Deubert SM, Mu\u0308ller-Hermelink HK. Differential diagnosis between classical Hodgkin\u2019s lymphoma, T-cell-rich B-cell lymphoma and paragranuloma by paraffin immunochemistry. Am J Surg Pathol. 1998;22:1184\u20131191.","DOI":"10.1097\/00000478-199810000-00003"},{"key":"2019111702054880600_R25","doi-asserted-by":"crossref","unstructured":"Felgar RE, Steward KR, Cousar JB, Macon WR. T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol. 1998;153:1707\u20131715.","DOI":"10.1016\/S0002-9440(10)65685-4"},{"key":"2019111702054880600_R26","doi-asserted-by":"crossref","unstructured":"Nogova L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma\u2014comparison of outcomes. Eur J Haematol Suppl. 2005:106\u2013110.","DOI":"10.1111\/j.1600-0609.2005.00462.x"},{"key":"2019111702054880600_R27","doi-asserted-by":"crossref","unstructured":"Crennan E, D\u2019Costa I, Liew KH, et al. Lymphocyte predominant Hodgkin\u2019s disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys. 1995;31:333\u2013337.","DOI":"10.1016\/0360-3016(94)E0136-8"},{"key":"2019111702054880600_R28","doi-asserted-by":"crossref","unstructured":"Pappa VI, Norton AJ, Gupta RK, Wilson AM, Rohatiner AZ, Lister TA. Nodular type of lymphocyte predominant Hodgkin\u2019s disease. A clinical study of 50 cases. Ann Oncol. 1995;6:559\u2013565.","DOI":"10.1093\/oxfordjournals.annonc.a059244"},{"key":"2019111702054880600_R29","unstructured":"von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin\u2019s disease. An immunohistochemical analysis of 208 reviewed Hodgkin\u2019s disease cases from the German Hodgkin Study Group. Am J Pathol. 1997;150:793\u2013803."},{"key":"2019111702054880600_R30","doi-asserted-by":"crossref","unstructured":"Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease. J Clin Oncol. 1997;15:3060\u20133066.","DOI":"10.1200\/JCO.1997.15.9.3060"},{"key":"2019111702054880600_R31","doi-asserted-by":"crossref","unstructured":"Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin\u2019s disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol. 1991;2 Suppl 2:77\u201382.","DOI":"10.1093\/annonc\/2.suppl_2.77"},{"key":"2019111702054880600_R32","doi-asserted-by":"crossref","unstructured":"Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101:420\u2013424.","DOI":"10.1182\/blood.V101.2.420"},{"key":"2019111702054880600_R33","doi-asserted-by":"crossref","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285\u20134289.","DOI":"10.1182\/blood-2002-08-2644"},{"key":"2019111702054880600_R34","doi-asserted-by":"crossref","unstructured":"Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683\u20131687.","DOI":"10.1093\/annonc\/mdi323"},{"key":"2019111702054880600_R35","doi-asserted-by":"crossref","unstructured":"Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221\u20131229.","DOI":"10.1002\/cncr.21303"},{"key":"2019111702054880600_R36","doi-asserted-by":"crossref","unstructured":"Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease. Cancer J. 2002;8:377\u2013383.","DOI":"10.1097\/00130404-200209000-00008"},{"key":"2019111702054880600_R37","doi-asserted-by":"crossref","unstructured":"Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin\u2019s lymphoma in children: therapeutic abstention after initial lymph node resection\u2014a Study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948\u20132952.","DOI":"10.1200\/JCO.2003.01.079"},{"key":"2019111702054880600_R38","doi-asserted-by":"crossref","unstructured":"Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684\u2013687.","DOI":"10.1097\/00043426-200309000-00003"},{"key":"2019111702054880600_R39","doi-asserted-by":"crossref","unstructured":"Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38 Suppl 4:S107\u2013113.","DOI":"10.1016\/S0959-8049(01)00446-4"},{"key":"2019111702054880600_R40","doi-asserted-by":"crossref","unstructured":"Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94:1731\u20131738.","DOI":"10.1002\/cncr.10404"},{"key":"2019111702054880600_R41","doi-asserted-by":"crossref","unstructured":"Feugier P, Labouyrie E, Djeridane M, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004;104:2675\u20132681.","DOI":"10.1182\/blood-2004-02-0567"},{"key":"2019111702054880600_R42","doi-asserted-by":"crossref","unstructured":"Henry-Amar M. Second cancer after the treatment for Hodgkin\u2019s disease: a report from the International Database on Hodgkin\u2019s Disease. Ann Oncol. 1992;3 Suppl 4:117\u2013128.","DOI":"10.1093\/annonc\/3.suppl_4.S117"},{"key":"2019111702054880600_R43","doi-asserted-by":"crossref","unstructured":"Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma. 2004;45:1551\u20131557.","DOI":"10.1080\/1042819031000149421"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/266\/1091593\/266_272ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/266\/1091593\/266_272ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:06:20Z","timestamp":1573974380000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/266\/19771\/Biology-Clinical-Course-and-Management-of-Nodular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.266","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}